RenovoRx, Inc.

The momentum for this stock is not very good. RenovoRx, Inc. is not a good value stock. RenovoRx, Inc. is not a good growth stock. RenovoRx, Inc. is a mediocre stock to choose.

News

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Globe Newswire LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ( RenovoRx or the Company ) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...\n more…

RenovoRx (NASDAQ:RNXT) Stock Price Down 11%

Zolmax Shares of RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) dropped 11% during trading on Monday . The company traded as low as $1.05 and last traded at $1.05. Approximately 29,982 shares changed hands...\n more…

RenovoRx (NASDAQ:RNXT) Releases Quarterly Earnings Results

Ticker Report RenovoRx (NASDAQ:RNXT - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, reports. RenovoRx Stock Performance NASDAQ RNXT opened at...\n more…

RenovoRx announces first patient enrolled at UNMC for Phase III TIGeR-PaC trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Globe Newswire Phase III clinical trial is evaluating RenovoGem for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites...\n more…

RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nRNXT stock results show that RenovoRx met analyst estimates for earnings per share the second quarter of 2024.\nThe post RNXT Stock...\n more…